Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir

Academic Article

Abstract

  • © 2016 The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed. Clinical Trials Registration. NCT02073656.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Cooper C; Naggie S; Saag M; Yang JC; Stamm LM; Dvory-Sobol H; Han L; Pang PS; McHutchison JG; Dieterich D
  • Start Page

  • 528
  • End Page

  • 531
  • Volume

  • 63
  • Issue

  • 4